Developer docs
API playgroundTry for free, no card

Search company profiles

Apotex Inc.

Full company profile

uuid005o172

Namestring
Apotex Inc.
Legal namestring
Apotex Inc.
Websiteurl
apotex.com
Company typeenum
Public
Founded yearint
1974
Descriptiontext

Apotex Inc., operating as Apotex Health Corp. since its June 2026 IPO on the Toronto Stock Exchange (TSX: APTX), is a Canadian-based global pharmaceutical company founded in 1974 by Dr. Barry Sherman. The company operates four product divisions: Generics (approximately 460 products across ~70 countries, including oral solid doses, injectables, suspensions, sprays, and inhalers), Biosimilars through wholly owned subsidiary Apobiologix (with leading oncology biosimilars including Grastofil, Lapelga, Bambevi, and Toripalimab in Canada), Innovative and Specialty Medicines through Searchlight Pharma (65+ branded products), and Consumer Health (vitamins, supplements, and natural health products through CanPrev, Orange Naturals, and Cyto-Matrix). Apotex also operates DISpedia, a drug information service for healthcare professionals, and the Apotex Global Health Access Fund for health equity programs.

Apotex serves a B2B customer base including healthcare providers, hospitals, pharmacies, payers, and government health programs, with a sales-led and channel-partner distribution model reaching approximately 75 countries. The company holds the #1 position in Canadian prescription volume, top-five status in the US generics market, and #4 in Mexico's private generics market. Manufacturing is vertically integrated across six world-class finished-dose manufacturing sites plus three API sites in Canada, the United States, Mexico, and India, with approximately 25 billion finished doses produced annually. R&D investment exceeds $2 billion over the past decade, yielding dozens of new product launches each year.

The business model is unit-pricing revenue from high-volume generic and specialty product sales, with pricing negotiated through healthcare systems, pharmacy benefit managers, and government drug programs rather than publicly disclosed. In July 2026, Apotex acquired Cumberland Pharmaceuticals' U.S. branded businesses for $100 million, secured an amended $1.2 billion credit facility, and received an inaugural BBB (low) investment-grade rating from Morningstar DBRS. The company employs 6,000+ team members globally and has a 20-year partnership with Health Partners International Canada supporting medicine donations to more than 33 million people across 100 countries.

Short descriptiontext

Apotex Health Corp. (TSX: APTX) is a Canadian-based global pharmaceutical company manufacturing generics, biosimilars, specialty medicines, and consumer health products. It serves hospitals, pharmacies, and payers across approximately 75 countries from six manufacturing sites producing 25 billion doses annually.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, biosimilar medicines, specialty branded drugs, consumer health products, active pharmaceutical ingredients
Industry4 codes
1Small-Molecule Generics (Branded/Unbranded)
CodeHLAIABAAPrimaryYes
2Generic Finished Dosage Form (FDF) Manufacturing
CodeHLAIABAHPrimaryNo
3Generic APIs & Intermediates (Active Ingredients)
CodeHLAIABAGPrimaryNo
4Generic Hospital & Institutional Products
CodeHLAIABALPrimaryNo
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Generic Pharmaceuticals
TypeOne Time License
Description

Sale of generic medicines including oral solid doses, suspensions, capsules, injectables, sprays, powders, inhalers, and drops. ~460 generic products distributed across ~70 countries. Revenue from prescription volume and market share in Canada, US, and Mexico.

apotex.com
2Innovative & Specialty Medicines
TypeOne Time License
Description

Branded pharmaceutical products through Searchlight Pharma division. Over 65 branded products in various therapeutic areas providing breakthrough treatments.

apotex.com
3Biosimilars
TypeOne Time License
Description

Biosimilar medicines through Apobiologix. High-quality, cost-effective biologic treatments beginning with oncology and expanding into other high-impact therapeutic areas.

apotex.com
4Consumer Health Products
TypeOne Time License
Description

Over-the-counter and natural health products through brands including CanPrev, Orange Naturals, and Cyto-Matrix. Vitamins, supplements, and natural health products designed by licensed practitioners.

apotex.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Generic pharmaceuticals at affordable prices compared to branded alternatives
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Generic medications offered at significantly lower prices than branded equivalents, providing cost-effective access to essential medicines

apotex.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Apobiologix
Description

Makes advanced biologic treatments more accessible through high-quality biosimilars in oncology and emerging areas. Products include Grastofil, Lapelga, Bambevi, and Toripalimab.

apotex.com
+4 more records
Core offering1 text field

Apotex is a vertically integrated global pharmaceutical manufacturer that develops, produces, and distributes approximately 460 generic pharmaceutical products across ~70 countries. The company's portfolio spans generics, biosimilars (through Apobiologix), innovative branded specialty medicines (through Searchlight Pharma), and consumer health products (CanPrev, Orange Naturals, Cyto-Matrix). With six world-class manufacturing sites producing approximately 25 billion finished doses annually, Apotex holds the #1 position in Canadian prescription volume and ranks in the top 10 in the U.S. generics market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • $11 billion+ in healthcare system savings in Canada in the last five years
+5 more records
Product overview1 text field

Apotex Inc. is a Canadian-based global pharmaceutical company offering a diversified portfolio of healthcare products organized into four core divisions: Generics (approximately 460 generic pharmaceutical products distributed across ~70 countries, #1 in Canadian prescription volume, top 10 in US, #4 in Mexico's private generics market), Biosimilars through Apobiologix (leading oncology biosimilars including Grastofil, Lapelga, Bambevi, and Toripalimab), Innovative & Specialty Medicines through Searchlight Pharma (65+ branded products targeting specialty care), and Consumer Health (vitamins, supplements, and natural health products through CanPrev, Orange Naturals, and CytoMatrix brands). The company also provides drug information services through DISpedia and operates the Apotex Global Health Access Fund for health equity initiatives. With manufacturing capacity of approximately 25 billion finished doses annually across six facilities, Apotex serves markets in ~70 countries worldwide.

Product and service7 records
1Generic Pharmaceuticals
CategoryGeneric pharmaceuticals
Description

Approximately 460 generic pharmaceutical products including oral solid doses, suspensions, capsules, injectables, sprays, powders, inhalers, and drops, distributed across ~70 countries for hospitals, pharmacies, and healthcare systems.

2Biosimilars (Apobiologix)
CategoryBiosimilars
Description

High-quality, cost-effective biosimilar medicines developed and commercialized through Apobiologix, with leading positions in oncology biosimilars and expansion into other therapeutic areas.

3Innovative and Specialty Medicines (Searchlight Pharma)
CategoryBranded specialty pharmaceuticals
Description

More than 65 branded pharmaceutical products targeting unmet needs in specialty care across various therapeutic areas including dermatology, allergy, pain management, ophthalmology, and women's health.

4Consumer Health Products (CanPrev, Orange Naturals, Cyto-Matrix)
CategoryConsumer health and natural products
Description

Vitamins, supplements, and natural health products designed by licensed practitioners for optimal health and well-being, distributed through CanPrev, Orange Naturals, and Cyto-Matrix brands.

5Generic Infuvite Adult and Pediatric Injection
CategoryGeneric injectable pharmaceuticals
Description

Four configurations of generic equivalents of Infuvite Pediatric and Adult Injection products launched into the U.S. hospital market, with two configurations receiving Competitive Generic Therapy (CGT) exclusivity.

6SEVMIA (Generic Semaglutide)
CategoryGeneric pharmaceuticals
Description

Generic semaglutide for chronic weight management; Apotex was the first company to receive Health Canada approval for this product.

7Sitagliptin Tablets and Sitagliptin/Metformin Hydrochloride Tablets
CategoryGeneric pharmaceuticals
Description

Generic sitagliptin tablets and sitagliptin/metformin hydrochloride combination tablets eligible for 180-day shared exclusivity in the U.S. market.

Scale indicator20 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-07-08
Description

Collaboration for development of generic Infuvite Adult and Pediatric Injection products. Orbicular provides technical expertise in complex generic and specialty pharmaceutical product development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-07-08
Description

Partnership for development and manufacturing of generic Infuvite products. Gland Pharma is a leading injectable-focused pharmaceutical company specializing in sterile injectable products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-06
Description

Strategic transaction to integrate Cumberland's U.S. branded businesses into Apotex for $100 million in cash. Completed July 1, 2026. This deal marks a major shift for Apotex to expand its branded pharmaceutical portfolio.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2005-01-01
Description

20-year partnership for global medicine donation program. HPIC has helped more than 33 million people across 100 countries gain access to medications. Apotex has provided over $45 million in medicine donations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Apotex subsidiary focused on biosimilar development. Leading in oncology biosimilars with top-selling products in Canada including Grastofil, Lapelga, Bambevi, and Toripalimab.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Apotex specialty pharma division focused on innovative branded pharmaceuticals. Expanding portfolio of pain management and allergy products.

Strategic tierAdjacentTypeStrategic or Co-development Partner
Description

Consumer health brand under Apotex offering vitamins, supplements, and natural health products designed by licensed practitioners.

Strategic tierAdjacentTypeStrategic or Co-development Partner
Description

Consumer health brand offering natural health products distributed through established channels.

Strategic tierAdjacentTypeStrategic or Co-development Partner
Description

Consumer health brand focused on practitioner-formulated vitamins and supplements.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Partnership to expand into new markets with branded pharmaceuticals.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Partnership to enter Canadian market through Apotex for ophthalmology products including IHEEZO and other eye care treatments.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty and generics pharmaceutical company with significant US footprint across injectables, generics, and branded specialty. Comparable in US generics and specialty portfolio breadth.

TypeDirect peer
Description

Novartis spin-off and #2 global generics player with strong small-molecule generics and biosimilars businesses. Directly comparable as a vertically integrated generic and biosimilar manufacturer serving multiple geographies.

TypeDirect peer
Description

India-based global generic pharmaceutical manufacturer with strong US and emerging market presence. Comparable in API manufacturing capability, generics portfolio breadth, and specialty branded expansion.

TypeDirect peer
Description

Global generics and specialty pharmaceutical company formed from Mylan-Upjohn combination. Comparable in scale and breadth across generics, branded specialty, and biosimilars with similar global distribution model.

TypeDirect peer
Description

Indian global pharmaceutical company with integrated API-to-generics operations across North America, Europe, and emerging markets. Comparable in vertically integrated generics, biosimilars, and specialty pharma.

TypeDirect peer
Description

Large Indian generic pharmaceutical manufacturer with strong US generics presence and growing European footprint. Comparable in scale of US generics business, API integration, and emerging biosimilars investments.

TypeDirect peer
Description

Generic and specialty pharmaceutical company with strong US hospital injectables presence and MENA regional leadership. Comparable in hospital/institutional generics focus and specialty branded portfolio.

TypeRegional player
Description

Canadian-headquartered specialty pharmaceutical company with diversified branded generics, branded pharma, and consumer health businesses. Comparable as a major Canadian-headquartered pharmaceutical peer with similar portfolio breadth and product diversification.

TypeDirect peer
Description

World's largest generic pharmaceuticals manufacturer with extensive oral solid dose, API, and biosimilars capabilities across global markets. Most directly comparable peer given scale, broad generic portfolio, and biosimilars presence.

TypeDirect peer
Description

India-headquartered global generics company with significant US and emerging market presence. Comparable in oral solid dose generics manufacturing, complex generics focus, and biosimilars pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apotex Inc.

Generic Pharmaceuticalsapotex.com

Apotex Health Corp. (TSX: APTX) is a Canadian-based global pharmaceutical company manufacturing generics, biosimilars, specialty medicines, and consumer health products. It serves hospitals, pharmacies, and payers across approximately 75 countries from six manufacturing sites producing 25 billion doses annually.

What Apotex Inc. does

Apotex Inc., operating as Apotex Health Corp. since its June 2026 IPO on the Toronto Stock Exchange (TSX: APTX), is a Canadian-based global pharmaceutical company founded in 1974 by Dr. Barry Sherman. The company operates four product divisions: Generics (approximately 460 products across ~70 countries, including oral solid doses, injectables, suspensions, sprays, and inhalers), Biosimilars through wholly owned subsidiary Apobiologix (with leading oncology biosimilars including Grastofil, Lapelga, Bambevi, and Toripalimab in Canada), Innovative and Specialty Medicines through Searchlight Pharma (65+ branded products), and Consumer Health (vitamins, supplements, and natural health products through CanPrev, Orange Naturals, and Cyto-Matrix). Apotex also operates DISpedia, a drug information service for healthcare professionals, and the Apotex Global Health Access Fund for health equity programs.

Apotex serves a B2B customer base including healthcare providers, hospitals, pharmacies, payers, and government health programs, with a sales-led and channel-partner distribution model reaching approximately 75 countries. The company holds the #1 position in Canadian prescription volume, top-five status in the US generics market, and #4 in Mexico's private generics market. Manufacturing is vertically integrated across six world-class finished-dose manufacturing sites plus three API sites in Canada, the United States, Mexico, and India, with approximately 25 billion finished doses produced annually. R&D investment exceeds $2 billion over the past decade, yielding dozens of new product launches each year.

The business model is unit-pricing revenue from high-volume generic and specialty product sales, with pricing negotiated through healthcare systems, pharmacy benefit managers, and government drug programs rather than publicly disclosed. In July 2026, Apotex acquired Cumberland Pharmaceuticals' U.S. branded businesses for $100 million, secured an amended $1.2 billion credit facility, and received an inaugural BBB (low) investment-grade rating from Morningstar DBRS. The company employs 6,000+ team members globally and has a 20-year partnership with Health Partners International Canada supporting medicine donations to more than 33 million people across 100 countries.

Apotex Inc. firmographics

Firmographics
Name
Apotex Inc.
Legal name
Apotex Inc.
Website
https://apotex.com
Company type
Public
Founded year
1974
Operating status
Operating
Short description
Apotex Health Corp. (TSX: APTX) is a Canadian-based global pharmaceutical company manufacturing generics, biosimilars, specialty medicines, and consumer health products. It serves hospitals, pharmacies, and payers across approximately 75 countries from six manufacturing sites producing 25 billion doses annually.
Ownership category
akta.pro rank

Apotex Inc. industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
akta.pro secondary industries
Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

  • Generic pharmaceuticals
  • Biosimilar medicines
  • Specialty branded drugs
  • Consumer health products
  • Active pharmaceutical ingredients

Where Apotex Inc. is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices6 records

Markets served

Apotex Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Generic Pharmaceuticals: Sale of generic medicines including oral solid doses, suspensions, capsules, injectables, sprays, powders, inhalers, and drops. ~460 generic products distributed across ~70 countries. Revenue from prescription volume and market share in Canada, US, and Mexico.
  2. Innovative & Specialty Medicines: Branded pharmaceutical products through Searchlight Pharma division. Over 65 branded products in various therapeutic areas providing breakthrough treatments.
  3. Biosimilars: Biosimilar medicines through Apobiologix. High-quality, cost-effective biologic treatments beginning with oncology and expanding into other high-impact therapeutic areas.
  4. Consumer Health Products: Over-the-counter and natural health products through brands including CanPrev, Orange Naturals, and Cyto-Matrix. Vitamins, supplements, and natural health products designed by licensed practitioners.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goGeneric pharmaceuticals at affordable prices compared to branded alternatives

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Apotex Inc. product offering

Product offering

Core offering

Apotex is a vertically integrated global pharmaceutical manufacturer that develops, produces, and distributes approximately 460 generic pharmaceutical products across ~70 countries. The company's portfolio spans generics, biosimilars (through Apobiologix), innovative branded specialty medicines (through Searchlight Pharma), and consumer health products (CanPrev, Orange Naturals, Cyto-Matrix). With six world-class manufacturing sites producing approximately 25 billion finished doses annually, Apotex holds the #1 position in Canadian prescription volume and ranks in the top 10 in the U.S. generics market.

Product overview

Apotex Inc. is a Canadian-based global pharmaceutical company offering a diversified portfolio of healthcare products organized into four core divisions: Generics (approximately 460 generic pharmaceutical products distributed across ~70 countries, #1 in Canadian prescription volume, top 10 in US, #4 in Mexico's private generics market), Biosimilars through Apobiologix (leading oncology biosimilars including Grastofil, Lapelga, Bambevi, and Toripalimab), Innovative & Specialty Medicines through Searchlight Pharma (65+ branded products targeting specialty care), and Consumer Health (vitamins, supplements, and natural health products through CanPrev, Orange Naturals, and CytoMatrix brands). The company also provides drug information services through DISpedia and operates the Apotex Global Health Access Fund for health equity initiatives. With manufacturing capacity of approximately 25 billion finished doses annually across six facilities, Apotex serves markets in ~70 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • Apobiologix: Makes advanced biologic treatments more accessible through high-quality biosimilars in oncology and emerging areas. Products include Grastofil, Lapelga, Bambevi, and Toripalimab.
  • Searchlight Pharma
  • CanPrev
  • Orange Naturals
  • Cyto-Matrix

Products and services

  • Generic Pharmaceuticals Approximately 460 generic pharmaceutical products including oral solid doses, suspensions, capsules, injectables, sprays, powders, inhalers, and drops, distributed across ~70 countries for hospitals, pharmacies, and healthcare systems.
  • Biosimilars (Apobiologix) High-quality, cost-effective biosimilar medicines developed and commercialized through Apobiologix, with leading positions in oncology biosimilars and expansion into other therapeutic areas.
  • Innovative and Specialty Medicines (Searchlight Pharma) More than 65 branded pharmaceutical products targeting unmet needs in specialty care across various therapeutic areas including dermatology, allergy, pain management, ophthalmology, and women's health.
  • Consumer Health Products (CanPrev, Orange Naturals, Cyto-Matrix) Vitamins, supplements, and natural health products designed by licensed practitioners for optimal health and well-being, distributed through CanPrev, Orange Naturals, and Cyto-Matrix brands.
  • Generic Infuvite Adult and Pediatric Injection Four configurations of generic equivalents of Infuvite Pediatric and Adult Injection products launched into the U.S. hospital market, with two configurations receiving Competitive Generic Therapy (CGT) exclusivity.
  • SEVMIA (Generic Semaglutide) Generic semaglutide for chronic weight management; Apotex was the first company to receive Health Canada approval for this product.
  • Sitagliptin Tablets and Sitagliptin/Metformin Hydrochloride Tablets Generic sitagliptin tablets and sitagliptin/metformin hydrochloride combination tablets eligible for 180-day shared exclusivity in the U.S. market.

Quantifiable outcome

  • $11 billion+ in healthcare system savings in Canada in the last five years
  • +5 more outcomes

Companies that use Apotex Inc.

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Apotex Inc. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Apotex Inc. partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, adjacent and strategic.

  • Orbicular Pharmaceutical Technologies Pvt. Ltd.coreTechnology or Integration · 8 July 2026Collaboration for development of generic Infuvite Adult and Pediatric Injection products. Orbicular provides technical expertise in complex generic and specialty pharmaceutical product development.
  • Gland Pharma LimitedcoreTechnology or Integration · 8 July 2026Partnership for development and manufacturing of generic Infuvite products. Gland Pharma is a leading injectable-focused pharmaceutical company specializing in sterile injectable products.
  • Cumberland PharmaceuticalscoreStrategic or Co-development Partner · 6 May 2026Strategic transaction to integrate Cumberland's U.S. branded businesses into Apotex for $100 million in cash. Completed July 1, 2026. This deal marks a major shift for Apotex to expand its branded pharmaceutical portfolio.
  • Health Partners International Canada (HPIC)coreStrategic or Co-development Partner · 1 January 200520-year partnership for global medicine donation program. HPIC has helped more than 33 million people across 100 countries gain access to medications. Apotex has provided over $45 million in medicine donations.
  • ApobiologixcoreStrategic or Co-development PartnerApotex subsidiary focused on biosimilar development. Leading in oncology biosimilars with top-selling products in Canada including Grastofil, Lapelga, Bambevi, and Toripalimab.
  • Searchlight PharmacoreStrategic or Co-development PartnerApotex specialty pharma division focused on innovative branded pharmaceuticals. Expanding portfolio of pain management and allergy products.
  • CanPrevadjacentStrategic or Co-development PartnerConsumer health brand under Apotex offering vitamins, supplements, and natural health products designed by licensed practitioners.
  • Orange NaturalsadjacentStrategic or Co-development PartnerConsumer health brand offering natural health products distributed through established channels.
  • Cyto-MatrixadjacentStrategic or Co-development PartnerConsumer health brand focused on practitioner-formulated vitamins and supplements.
  • Formosa PharmastrategicStrategic or Co-development PartnerPartnership to expand into new markets with branded pharmaceuticals.
  • HarrowstrategicStrategic or Co-development PartnerPartnership to enter Canadian market through Apotex for ophthalmology products including IHEEZO and other eye care treatments.

Scale indicators20 records

Recent moves7 records

Expansion highlights6 records

Apotex Inc. competitors and assessment

Company assessment

Direct peers

  • Endo International: Specialty and generics pharmaceutical company with significant US footprint across injectables, generics, and branded specialty. Comparable in US generics and specialty portfolio breadth.
  • Sandoz: Novartis spin-off and #2 global generics player with strong small-molecule generics and biosimilars businesses. Directly comparable as a vertically integrated generic and biosimilar manufacturer serving multiple geographies.
  • Sun Pharmaceutical Industries: India-based global generic pharmaceutical manufacturer with strong US and emerging market presence. Comparable in API manufacturing capability, generics portfolio breadth, and specialty branded expansion.
  • Viatris: Global generics and specialty pharmaceutical company formed from Mylan-Upjohn combination. Comparable in scale and breadth across generics, branded specialty, and biosimilars with similar global distribution model.
  • Dr. Reddy's Laboratories: Indian global pharmaceutical company with integrated API-to-generics operations across North America, Europe, and emerging markets. Comparable in vertically integrated generics, biosimilars, and specialty pharma.
  • Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with strong US generics presence and growing European footprint. Comparable in scale of US generics business, API integration, and emerging biosimilars investments.
  • Hikma Pharmaceuticals: Generic and specialty pharmaceutical company with strong US hospital injectables presence and MENA regional leadership. Comparable in hospital/institutional generics focus and specialty branded portfolio.
  • Teva Pharmaceutical Industries: World's largest generic pharmaceuticals manufacturer with extensive oral solid dose, API, and biosimilars capabilities across global markets. Most directly comparable peer given scale, broad generic portfolio, and biosimilars presence.
  • Lupin Pharmaceuticals: India-headquartered global generics company with significant US and emerging market presence. Comparable in oral solid dose generics manufacturing, complex generics focus, and biosimilars pipeline.

Regional players

  • Bausch Health: Canadian-headquartered specialty pharmaceutical company with diversified branded generics, branded pharma, and consumer health businesses. Comparable as a major Canadian-headquartered pharmaceutical peer with similar portfolio breadth and product diversification.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Apotex Inc. social profiles

Digital presence

Apotex Inc. compliance and trust

Trust signal

Compliance6 records

Apotex Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apotex Inc. leadership team

Management profile

Number of profiles

Profiles17 records

Apotex Inc. subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Apotex Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apotex Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apotex Inc.

What does Apotex Inc. do?

Apotex is a vertically integrated global pharmaceutical manufacturer that develops, produces, and distributes approximately 460 generic pharmaceutical products across ~70 countries. The company's portfolio spans generics, biosimilars (through Apobiologix), innovative branded specialty medicines (through Searchlight Pharma), and consumer health products (CanPrev, Orange Naturals, Cyto-Matrix). With six world-class manufacturing sites producing approximately 25 billion finished doses annually, Apotex holds the #1 position in Canadian prescription volume and ranks in the top 10 in the U.S. generics market.

Is Apotex Inc. a public or private company?

Apotex Inc. is a public company. It is classified as public and is currently operating.

When was Apotex Inc. founded?

Apotex Inc. was founded in 1974.

Where is Apotex Inc. based?

Apotex Inc. is headquartered in Toronto, Canada, in the North America region.

How does Apotex Inc. make money?

Four revenue lines are on record. Generic Pharmaceuticals are the primary driver. The others are innovative & Specialty Medicines, biosimilars and consumer Health Products.

Who are Apotex Inc.'s main competitors?

Direct peers on record are Endo International, Sandoz, Sun Pharmaceutical Industries, Viatris, Dr. Reddy's Laboratories, Aurobindo Pharma, Hikma Pharmaceuticals, Teva Pharmaceutical Industries and Lupin Pharmaceuticals. Bausch Health is listed as a regional player.

Does Apotex Inc. have an API?

No public API is recorded for Apotex Inc..

What industry is Apotex Inc. in?

Apotex Inc.'s product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StApotex Health (TSX:APTX) Stock May Trade At A Premium As Its Secondary Offering GrowsApotex Health's stock is up 23.2% year to date, trading at a price-to-sales ratio of 2.4x, above the pharmaceuticals industry average of 1.1x. The company's upsized secondary offering at $34 per share may influence how the market weighs future growth against existing shareholder supply.MarketScreenerApotex Health shares jump in largest Toronto stock market IPO since 2021Apotex Health shares jumped on its Toronto debut, with the IPO raising about C$1.3 billion in gross proceeds, the largest TSX IPO since 2021. The company priced 54.17 million shares at $24, the top of the range, and the stock opened 17% above the IPO price.WsjHealth Care Roundup: Market TalkApotex Health upsized its IPO to 54.2-65 million shares at C$20-24, seeking C$1.3 billion. The increase signals strong demand, making it the largest IPO since Definity Financial's 2021 debut. The company will join TSX-listed pharma peers like Bausch Health and Knight Therapeutics.sharewiseCumberland Posts Loss in Q1 Amid $100M Apotex Deal PlanCumberland Pharmaceuticals reported a first-quarter 2026 net loss of $3.3 million and announced a strategic transaction to sell its portfolio of FDA-approved brands to Apotex Inc. for $100 million in cash. This deal marks a major shift for Cumberland from a commercial-stage pharmaceutical business to a development-focused biopharmaceutical company centered on orphan and specialty drug candidates.BioSpaceApotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical CompanyApotex Inc. has completed its acquisition of Searchlight Pharma Inc., a Canadian specialty pharmaceutical company, integrating it as the new Specialty Pharma Division under Apotex. This strategic move is intended to accelerate Apotex's growth in the innovative branded pharmaceutical market and diversify its portfolio beyond generic medicines.NewswireApotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical CompanyApotex Inc. has completed the acquisition of Searchlight Pharma Inc., a Canadian specialty innovative branded pharmaceutical company, integrating it as the new Specialty Pharma Division under Apotex. This strategic move is designed to accelerate Apotex's growth in the specialty market and diversify its portfolio beyond traditional generic pharmaceuticals.Consumer NoticeApotex Eye Drops: Uses, Dosage, Side Effects & MoreApotex Inc. produces various ophthalmic solutions, including Brimonidine Tartrate, Ofloxacin, and Olopatadine, for treating conditions such as glaucoma, bacterial infections, and allergic conjunctivitis. The U.S. Food and Drug Administration is implementing new regulatory requirements for eye drops classified as drug-device combinations. Additionally, Apotex initiated a voluntary recall in March 2023 for specific lots of Brimonidine Tartrate due to potential sterility issues caused by bottle cracks.